President Donald Trump recently voiced frustration in the Oval Office, stating "You know, they're slow-walking me on rescheduling. You're going to get it done, right?" four months after signing a December 2025 executive order directing the Attorney General to expedite marijuana's move from Schedule I to Schedule III of the Controlled Substances Act in the "most expeditious manner." This public complaint, made during a psychedelics research expansion event, highlights not just administrative delays but deeper internal tensions within federal drug policy. Longtime Trump advisor Roger Stone has publicly claimed someone inside the administration is "holding up" the process, coming amid the firing of Attorney General Pam Bondi—who previously opposed marijuana reform in Florida—and the interim role of Todd Blanche.

Going beyond surface-level reporting, this episode reveals entrenched bureaucratic and institutional resistance that persists even under a directive from the President. The Department of Justice and DEA have procedural levers, including administrative hearings and stakeholder consultations, that can extend timelines indefinitely—tactics that echo decades of federal foot-dragging on cannabis despite state-level legalization in over 30 states. This friction has major implications for criminal justice: rescheduling would acknowledge medical use, ease certain research barriers, and crucially end the IRS 280E tax penalty that has crippled state-legal operators, potentially reducing the incentive for black market activity and related violence. However, it stops short of full descheduling, leaving recreational users and small businesses in a federal gray zone and limiting broader expungements or reparations for the war on drugs' disproportionate impact on minority communities.

From a states' rights perspective, the delay underscores federalism's strains. While states have pioneered regulated markets, banking access, and public safety measures—as evidenced by coalitions of 35 cannabis groups, labor unions like UFCW, and reform organizations urging Congress to pass the SAFE Banking Act to combat dispensary robberies in places like Washington state—the federal government's lag perpetuates conflicts. Without rescheduling or banking reform, cash-heavy businesses remain targets, as documented in reports of over 100 robberies at 80+ Washington dispensaries between 2021-2022, endangering workers, customers, and bystanders. Trump's push, if realized, could reduce federal preemption and validate state experimentation, aligning with heterodox views that the drug war represents unconstitutional overreach.

Connections often missed include the role of entrenched pharmaceutical interests. Schedule III status would facilitate FDA-approved cannabis-derived medications, opening competition against patented opioids, anxiolytics, and pain treatments—a direct threat to a multi-billion-dollar industry that has historically lobbied against cannabis due to its natural, hard-to-patent profile. By recognizing therapeutic value (as the EO's fact sheet emphasizes for research expansion alongside CBD), this reform could disrupt pharma's dominance in addressing the very crises (addiction, chronic pain) exacerbated by overprescription of synthetics. Internal administration turmoil, including AG transitions, may reflect these competing lobbies and ideological divides between reform-minded populists and traditional law-and-order factions. Ultimately, Trump's visible impatience signals a populist challenge to administrative state inertia, with potential to accelerate comprehensive reform or further empower states to decriminalize independently. Real progress requires navigating these tensions, or the "humanitarian toll" of prohibition's remnants—from robberies to unnecessary incarceration—will persist. Sources confirm the EO's directives, ongoing delays, and policy ripple effects across criminal justice, federalism, and industry economics.